This is a T2D. news story, published by The Daily.
For more T2D. news, you can click here:
more T2D. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from The Daily, you can click here:
more news from The DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
diabetes. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest popular diabetes news, blood sugar news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
AlzheimerThe Daily
•
88% Informative
Semaglutide is a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in T2D.
About 120,000 Americans die from Alzheimer’s disease each year, with the disease listed as seventh -leading cause of death nationally.
VR Score
91
Informative language
93
Neutral language
46
Article tone
formal
Language
English
Language complexity
79
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
4
Affiliate links
no affiliate links